Table 3-.
The study | Number of patients | Cardiac involvement % | Complete Hematological response % | Organ response % | Treatment related mortality % | Median PFS/OS |
---|---|---|---|---|---|---|
Gertz 2010 | 434 | Not rported | 39 | 47 | 10 | Complete response >120 m Partial response 107m No response 32 m |
Sanchorawala Blood 2011 | 421 | 45 | 34 | 53 | 11.4 | Med OS 75m |
Sanchorawala 2014 | 607 | 53 | 34 | NR | 9 | Med OS 80m |
Parmar 2014 | 80 | 23 | 19 | 39 | 12.5 | 5 years OS 72% |
Jaccard 2007 | 100 - randomized to ASCT or MP | 73 | No significant difference between the two treatment groups (47% Vs 61%) | No significant difference between the two treatment groups | 24 | Med OS was 56.9 months in the MP arm and 22.2 months in the ASCT arm (P=0.04) |
Gertz 2016 | 89 – randomized to ASCT (55) or Mel dex (39) | 41 in mel dex arm and 15 in ASCT arm | 20, No significant difference between the two treatment groups | 30 No significant difference between the two treatment groups | 5.6 | 3-year PFS of 29.1% in mel dex arm and 51.7% in the ASCT arm. 3y OS was 58.8% in mel dex arm vs 83.6% in ASCT arm. |